TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $883.66m
- $528.80m
- $107.46m
Theravance Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Theravance Biopharma Q2 Operating Income USD -15.705 Million
Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Theravance Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Theravance Biopharma Q1 Operating Income USD -11.207 Million
Theravance Biopharma Inc expected to post a loss of 25 cents a share - Earnings Preview
Theravance Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Theravance Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Theravance Biopharma and Mylan Enter Into Settlement Agreement With Orbicular Pharmaceutical Technologies
U.S. STOCKS ON THE MOVE-CVS Health, Peloton, Eli Lilly
U.S. STOCKS ON THE MOVE-Conagra Brands, Voyager Therapeutics, McDonald's
Theravance Biopharma tumbles as lung disease drug fails to meet main goal
Brief: Theravance Biopharma's Lung Disease Drug Fails to Meet Main Goal of Study
Brief: Theravance Biopharma- On Dec 26 Units, Mylan Ireland & Mylan Specialty L.P. Entered Settlement Agreement With Accord Healthcare
Brief: Theravance Biopharma Announces Appointment Of Jeremy Grant To Board Of Directors
Brief: Viatris And Theravance Biopharma Announce Positive Top-Line Results From Yupelri (Revefenacin) Phase III Trial
Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Theravance Biopharma Gets Notice From Pfizer Terminating License Agreement